Business, energy, technology, markets and global industry news from Business News Today

Novartis

PharmaDeviceNews Novartis
Pharma & Biotech

Novartis acquires SNV4818 from Synnovation in $3bn deal to reclaim ground in mutant PI3Ka breast cancer space

Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.

Read More
Pharma & Biotech

Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove

Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.

Read More
Novartis advances ITP strategy with ianalumab
Pharma & Biotech

Could Novartis change the ITP playbook with just four doses of ianalumab?

Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.

Read More